Teva wins US patent case against generic birth control pill

The U.S. District Court for the District of Nevada has upheld a patent for Teva Pharmaceutical Industries Ltd’s Seasonique birth-control pill awarding summary judgement against generic drug maker Watson Pharmaceuticals Inc. Watson had sought to sell a U.S. generic version of Seasonique before the patent expires in January 2024.

Teva is however still involved in separate litigation in the U.S. District Court of New Jersey involving applications for generic versions of Seasonique from Mylan Inc and Lupin Ltd. The impact of the Nevada decision on those cases remians unclear.

Seasonique causes women to ovulate four times a year rather than monthly – hence the name.



Categories: Intellectual Property, Israel IP, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: